1
|
Hu CS, Han YL, Ge JB, Wu QH, Liu YN, Ma CS, Tkebuchava T, Hu DY. A novel management program for hypertension. Cardiovasc Diagn Ther 2015; 5:316-22. [PMID: 26331115 DOI: 10.3978/j.issn.2223-3652.2015.05.13] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2014] [Accepted: 05/11/2015] [Indexed: 11/14/2022]
Abstract
In this article, we describe a comprehensive management program for hypertension (HTN), based on the experience of leading cardiovascular centers in China. This comprehensive approach, adhering to a number of core principles, includes diagnosis and therapeutic interventions. Therapeutic management includes lifestyle changes, risk factor management and pharmacological intervention and should allow reliable lowering blood pressure (BP). Additional paragraphs discuss the relationship between paroxysmal atrial fibrillation (PAF), and HTN.
Collapse
Affiliation(s)
- Chun-Song Hu
- 1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China
| | - Ya-Ling Han
- 1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China
| | - Jun-Bo Ge
- 1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China
| | - Qing-Hua Wu
- 1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China
| | - Yan-Na Liu
- 1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China
| | - Chang-Sheng Ma
- 1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China
| | - Tengiz Tkebuchava
- 1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China
| | - Da-Yi Hu
- 1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China
| |
Collapse
|
2
|
Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010; 6:113-33. [PMID: 20448797 PMCID: PMC2860444 DOI: 10.2147/vhrm.s7857] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2010] [Indexed: 12/21/2022] Open
Abstract
Blockade of the renin–angiotensin system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by angiotensin II throughout the cardiovascular and renal continua. Telmisartan is an angiotensin II receptor blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure. In patients with mild-to-moderate hypertension, telmisartan has proved superior to other antihypertensive agents (valsartan, losartan, ramipril, perindopril, and atenolol) in controlling blood pressure particularly towards the end of the dosing interval. There is also clinical evidence that telmisartan reduces left ventricular hypertrophy, reduces arterial stiffness and the recurrence of atrial fibrillation, and confers renoprotection. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET®) study has demonstrated that telmisartan has similar cardiovascular protective effects to ramipril in a large, high-risk patient population but was better tolerated. The powerful and sustained blood pressure control apparent in clinical trials, together with cardiovascular protection and tolerability demonstrated in ONTARGET® means that telmisartan may be a preferred option for patients with hypertension.
Collapse
|